查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1631501

美國切片檢查市場規模、佔有率、趨勢分析報告：按類型、原因、部位和細分市場預測，2025-2030 年

U.S. Cancer Biopsy Market Size, Share & Trends Analysis Report By Type (Fine-needle Aspiration, Core Biopsy, Surgical Biopsy, Skin Biopsy/Punch Biopsy, Others), By Cause (Application), By Site (Organ), And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國切片檢查市場的成長和趨勢

根據 Grand View Research, Inc. 的一份新報告，美國癌症切片檢查市場預計到 2030 年將達到 201.8 億美元，2025 年至 2030 年期間的複合年成長率為 10.8%。美國癌症切片檢查市場的成長歸因於多參數磁振造影切片檢查活體組織切片的日益普及以及影像引導針活體組織切片在精準醫療應用中的日益普及。

預計未來幾年液態切片行業將呈指數級成長，參與生物製藥製造和基因組資料分析的公司不斷增加的投資和戰略舉措將發揮核心作用。 2022 年 4 月，Global Brain 投資 Craif, Inc.，開發一種用於早期癌症檢測的新型非侵入性尿液液態切片。

此外，液態切片的出現、活體組織切片臨床應用的不斷增加以及遺傳性癌症疾病品質和付款的進步是預計在未來幾年推動市場成長的一些因素。此外，癌症發生率的上升和老年人口的增加也可能推動市場成長。

此外，基於血液的多癌症早期檢測 (MCED) 技術的出現預計將在預測期內提供有利可圖的機會。 MCED 代表了未來癌症診斷和治療方式的模式轉移。 MCED 的巨大潛力在於使臨床醫生從篩檢少數癌症轉向篩檢大量癌症。

GRAIL 和 Exact Sciences 等開發商正在開發 MCED 測試。此外，美國國家癌症美國(NCI) 正在尋找研究和評估 MCED 測試的方法。 NCI 目前正在為 MCED 測試規劃臨床試驗和其他研究機會，並最近向測試開發人員發出了關於他們是否準備好參與研究舉措的資訊請求。

美國切片檢查市場的主要企業正在採取多項策略措施來擴大其在市場的佔有率。市場參與企業進行的主要活動是併購、合作、地理擴張和新產品發布。例如，2022 年 4 月，Medtronic與 GE Healthcare 合作，以滿足日益成長的門診病人護理需求。根據這項舉措，客戶可以獲得金融解決方案、廣泛的產品系列和卓越的服務。

美國癌症切片檢查市場報告重點

  • 細針抽吸治療領域佔據市場主導地位，2024 年的收入佔有率最大，為 32.2%。
  • 由於定期健康檢查和癌症早期發現的需求不斷成長，篩檢和監測領域在 2024 年佔據了市場最大收益佔有率。
  • 到 2024 年，由於乳癌發生率上升，乳房外科將佔據市場的大部分佔有率。乳癌是女性中最常見的癌症之一，需要頻繁進行診斷評估（包括切片檢查）以確定疾病的存在和階段。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章美國切片檢查市場變數、趨勢和範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析 – 波特五力分析
    • PESTLE分析

第 4 章美國癌症切片檢查市場：類型業務分析

  • 2024 年及 2030 年類型市場佔有率
  • 類型細分儀表板
  • 2018 年至 2030 年按類型分類的市場規模、預測與趨勢分析
  • 細針穿刺
  • 芯切片檢查
  • 手術切片檢查
  • 皮膚切片檢查/穿刺切片檢查
  • 其他

第 5 章美國癌症切片檢查市場：原因業務分析

  • 2024 年及 2030 年各地區市場佔有率
  • 原因細分儀表板
  • 2018 年至 2030 年按原因分類的市場規模、預測與趨勢分析
  • 篩檢和監測
  • 診斷
  • 研究與轉化研究
  • 製藥和生物製藥的發現和開發

第6章美國癌症切片檢查市場：站點業務分析

  • 2024 年及 2030 年零件市場佔有率
  • 身體部位細分儀表板
  • 2018 年至 2030 年按身體部位分類的市場規模、預測與趨勢分析
  • 肝
  • 胸部
  • 甲狀腺
  • 攝護腺
  • 子宮和子宮頸
  • 腎
  • 膀胱
  • 肺
  • 胰臟
  • 其他

第7章 競爭格局

  • 參與者概述
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • BD（Becton, Dickinson and Company）
    • IZI Medical Products
    • Johnson & Johnson Services, Inc.
    • Argon Medical Devices
    • SPECTRA MEDICAL DEVICES, LLC
    • Medtronic
    • Boston Scientific Corporation
    • CONMED Corporation
    • INRAD, Inc.
    • Thermo Fisher Scientific Inc.
Product Code: GVR-4-68039-467-3

U.S. Cancer Biopsy Market Growth & Trends:

The U.S. cancer biopsy market size is expected to reach USD 20.18 billion by 2030, registering a CAGR of 10.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the U.S. cancer biopsy market is attributed to the rise in the adoption of biopsies based on multi-parametric magnetic resonance imaging and the increasing popularity of image-guided needle biopsies in precision medicine applications.

The liquid biopsy industry is anticipated to expand at an exponential rate in the coming years, wherein increasing investments and strategic initiatives by the companies involved in biopharmaceutical manufacturing & genomic data analysis are anticipated to play a central role. In April 2022, Global Brain invested in Craif, Inc. to develop a novel noninvasive urinary liquid biopsy for the early detection of cancer.

Furthermore, the advent of liquid biopsies, rising clinical implementation of biopsies, and advancements in quality & payment pertaining to genetic cancer diseases are the factors expected to boost the market growth in the coming years. The increasing prevalence of cancer and the growing geriatric population are also likely to fuel market growth.

Moreover, the advent of blood-based multi-cancer early detection (MCED) technologies is going to offer lucrative opportunities during the forecast period. MCED represents a paradigm shift in how cancers will be diagnosed and treated in the future. The great promise of MCED is that it will enable clinicians to convert from screening a few cancers to screening individuals for many cancers.

Companies such as GRAIL, Exact Sciences Corporation are developing MCED tests. In addition, the National Cancer Institute (NCI) is looking at ways to study and evaluate MCED tests. NCI is currently designing clinical trials & other research opportunities for MCED tests, and recently issued a request for information from test developers on their readiness to participate in research initiatives.

Key companies operating in the U.S. cancer biopsy market have adopted several strategic initiatives to reinforce their market presence. Major undertakings by the market participants are mergers & acquisitions, collaborations & partnerships, regional expansions, and new product launches. For instance, in April 2022, Medtronic entered into collaboration with GE Healthcare to address the increasing need for outpatient care. Under this initiative, customers can access financial solutions, extensive product portfolios, and exceptional services.

U.S. Cancer Biopsy Market Report Highlights:

  • The fine-needle aspiration segment dominated the market with the largest revenue share of 32.2% in 2024, driven by the increasing prevalence of cancer and a growing preference for minimally invasive procedures.
  • The screening & monitoring segment dominated the market with the largest revenue share in 2024, attributable to the rising demand for regular health check-ups and early cancer detection.
  • The breast segment held a significant share of the market in 2024, driven by the rising incidence of breast cancer. As one of the most diagnosed cancers among women, breast cancer needs frequent diagnostic assessment, including biopsies, to determine the presence and stage of the disease.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Cause (Application)
    • 1.2.3. Site (Organ)
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Cancer Biopsy Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. U.S. Cancer Biopsy Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Billion)
  • 4.4. Fine-needle Aspiration
    • 4.4.1. Fine-needle Aspiration Market, 2018 - 2030 (USD Billion)
    • 4.4.2. Pharma-use
      • 4.4.2.1. Pharma-use Market, 2018 - 2030 (USD Billion)
    • 4.4.3. Clinical
      • 4.4.3.1. Clinical Market, 2018 - 2030 (USD Billion)
  • 4.5. Core Biopsy
    • 4.5.1. Core Biopsy Market, 2018 - 2030 (USD Billion)
    • 4.5.2. Pharma-use
      • 4.5.2.1. Pharma-use Market, 2018 - 2030 (USD Billion)
    • 4.5.3. Clinical
      • 4.5.3.1. Clinical Market, 2018 - 2030 (USD Billion)
  • 4.6. Surgical Biopsy
    • 4.6.1. Surgical Biopsy Market, 2018 - 2030 (USD Billion)
    • 4.6.2. Pharma-use
      • 4.6.2.1. Pharma-use Market, 2018 - 2030 (USD Billion)
    • 4.6.3. Clinical
      • 4.6.3.1. Clinical Market, 2018 - 2030 (USD Billion)
  • 4.7. Skin Biopsy /Punch Biopsy
    • 4.7.1. Skin Biopsy /Punch Biopsy Market, 2018 - 2030 (USD Billion)
    • 4.7.2. Pharma-use
      • 4.7.2.1. Pharma-use Market, 2018 - 2030 (USD Billion)
    • 4.7.3. Clinical
      • 4.7.3.1. Clinical Market, 2018 - 2030 (USD Billion)
  • 4.8. Others
    • 4.8.1. Others Market, 2018 - 2030 (USD Billion)
    • 4.8.2. Pharma-use
      • 4.8.2.1. Pharma-use Market, 2018 - 2030 (USD Billion)
    • 4.8.3. Clinical
      • 4.8.3.1. Clinical Market, 2018 - 2030 (USD Billion)

Chapter 5. U.S. Cancer Biopsy Market: Cause (Application) Business Analysis

  • 5.1. Cause (Application) Market Share, 2024 & 2030
  • 5.2. Cause (Application) Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Cause (Application), 2018 to 2030 (USD Billion)
  • 5.4. Screening & Monitoring
    • 5.4.1. Screening & Monitoring Market, 2018 - 2030 (USD Billion)
  • 5.5. Diagnostics
    • 5.5.1. Diagnostics Market, 2018 - 2030 (USD Billion)
  • 5.6. Investigational & Translational Research
    • 5.6.1. Investigational & Translational Research Market, 2018 - 2030 (USD Billion)
  • 5.7. Pharma & Biopharma Discovery & Development
    • 5.7.1. Pharma & Biopharma Discovery & Development Market, 2018 - 2030 (USD Billion)

Chapter 6. U.S. Cancer Biopsy Market: Site (Organ) Business Analysis

  • 6.1. Site (Organ) Market Share, 2024 & 2030
  • 6.2. Site (Organ) Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Site (Organ), 2018 to 2030 (USD Billion)
  • 6.4. Liver
    • 6.4.1. Liver, 2018 - 2030 (USD Billion)
  • 6.5. Breast
    • 6.5.1. Breast Market, 2018 - 2030 (USD Billion)
  • 6.6. Thyroid
    • 6.6.1. Thyroid Market, 2018 - 2030 (USD Billion)
  • 6.7. Prostate Gland
    • 6.7.1. Prostate Gland Market, 2018 - 2030 (USD Billion)
  • 6.8. Uterus & Cervix
    • 6.8.1. Uterus & Cervix Market, 2018 - 2030 (USD Billion)
  • 6.9. Kidney
    • 6.9.1. Kidney Market, 2018 - 2030 (USD Billion)
  • 6.10. Bladder
    • 6.10.1. Bladder Market, 2018 - 2030 (USD Billion)
  • 6.11. Lungs
    • 6.11.1. Lungs Market, 2018 - 2030 (USD Billion)
  • 6.12. Pancreas
    • 6.12.1. Pancreas Market, 2018 - 2030 (USD Billion)
  • 6.13. Others
    • 6.13.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. BD (Becton, Dickinson and Company)
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Type Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. IZI Medical Products
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Type Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Johnson & Johnson Services, Inc.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Type Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Argon Medical Devices
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Type Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. SPECTRA MEDICAL DEVICES, LLC
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Type Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Medtronic
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Type Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Boston Scientific Corporation
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Type Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. CONMED Corporation
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Type Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. INRAD, Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Type Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Thermo Fisher Scientific Inc.
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Type Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. U.S. cancer biopsy market, by type, 2018 - 2030 (USD Billion)
  • Table 4. U.S. cancer biopsy market, by cause (application), 2018 - 2030 (USD Billion)
  • Table 5. U.S. cancer biopsy market, by site (organ), 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 U.S. cancer biopsy market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Type outlook (USD Billion)
  • Fig. 10 Cause (application) outlook (USD Billion)
  • Fig. 11 Site (organ) outlook (USD Billion)
  • Fig. 12 Competitive landscape
  • Fig. 13 U.S. cancer biopsy market dynamics
  • Fig. 14 U.S. cancer biopsy market: Porter's five forces analysis
  • Fig. 15 U.S. cancer biopsy market: PESTLE analysis
  • Fig. 16 U.S. cancer biopsy market: Type segment dashboard
  • Fig. 17 U.S. cancer biopsy market: Type market share analysis, 2024 & 2030
  • Fig. 18 Fine-needle aspiration market, 2018 - 2030 (USD Billion)
  • Fig. 19 Pharma-use market, 2018 - 2030 (USD Billion)
  • Fig. 20 Clinical market, 2018 - 2030 (USD Billion)
  • Fig. 21 Core biopsy market, 2018 - 2030 (USD Billion)
  • Fig. 22 Pharma-use market, 2018 - 2030 (USD Billion)
  • Fig. 23 Clinical market, 2018 - 2030 (USD Billion)
  • Fig. 24 Surgical biopsy market, 2018 - 2030 (USD Billion)
  • Fig. 25 Pharma-use market, 2018 - 2030 (USD Billion)
  • Fig. 26 Clinical market, 2018 - 2030 (USD Billion)
  • Fig. 27 Skin biopsy /punch biopsy market, 2018 - 2030 (USD Billion)
  • Fig. 28 Pharma-use market, 2018 - 2030 (USD Billion)
  • Fig. 29 Clinical market, 2018 - 2030 (USD Billion)
  • Fig. 30 Others market, 2018 - 2030 (USD Billion)
  • Fig. 31 Pharma-use market, 2018 - 2030 (USD Billion)
  • Fig. 32 Clinical market, 2018 - 2030 (USD Billion)
  • Fig. 33 U.S. cancer biopsy market: Cause (application) segment dashboard
  • Fig. 34 U.S. cancer biopsy market: Cause (application) market share analysis, 2024 & 2030
  • Fig. 35 Screening & monitoring market, 2018 - 2030 (USD Billion)
  • Fig. 36 Diagnostics market, 2018 - 2030 (USD Billion)
  • Fig. 37 Investigational & translational research market, 2018 - 2030 (USD Billion)
  • Fig. 38 Pharma & biopharma discovery & development market, 2018 - 2030 (USD Billion)
  • Fig. 39 U.S. cancer biopsy market: Site (organ) segment dashboard
  • Fig. 40 U.S. cancer biopsy market: Site (organ) market share analysis, 2024 & 2030
  • Fig. 41 Liver market, 2018 - 2030 (USD Billion)
  • Fig. 42 Breast market, 2018 - 2030 (USD Billion)
  • Fig. 43 Thyroid market, 2018 - 2030 (USD Billion)
  • Fig. 44 Prostate gland market, 2018 - 2030 (USD Billion)
  • Fig. 45 Uterus & cervix market, 2018 - 2030 (USD Billion)
  • Fig. 46 Kidney market, 2018 - 2030 (USD Billion)
  • Fig. 47 Bladder market, 2018 - 2030 (USD Billion)
  • Fig. 48 Lungs market, 2018 - 2030 (USD Billion)
  • Fig. 49 Pancreas market, 2018 - 2030 (USD Billion)
  • Fig. 50 Others market, 2018 - 2030 (USD Billion)
  • Fig. 51 Company categorization
  • Fig. 52 Company market position analysis
  • Fig. 53 Strategic framework